AT06 / Axcynsis Therap - LARVOL DELTA

AT06 is a bispecific antibody drug conjugate targeting DLL3 and SEZ6 with potent activity in small cell lung cancer (SCLC) models (AACR 2026) - "In a low DLL3/SEZ6-expression model of SCLC (NCI-H82), AT06 displayed strong and durable tumor growth inhibition (>99%) at a 1 mg/kg dose. These data reflect a promising dual-targeting bispecific ADC therapeutic with the potential to address tumor heterogeneity and resistance mechanisms across a broader range of patients."

ADC • Bispecific • Brain Cancer • Endocrine Cancer • Glioblastoma • Lung Cancer • Neuroendocrine Carcinoma • Neuroendocrine Neoplasm • Oncology • Small Cell Lung Cancer • Solid Tumor • DLL3 • SEZ6

AT06. Single Cell Multi-omic Technologies for Resolving Genotype-Phenotype Relationships in Cancer (AACR 2026) - No abstract available

Oncology

AT06- Systematic Functional Approaches for Understanding and Targeting Cancer (AACR 2024) - "We will discuss how large-scale CRISPR viability datasets can help us identify context-specific dependencies, how PRIME editing can be used to identify resistant mutations on a large scale, and how innovative CRISPR-based strategies can help us identify drivers of copy number alterations. Finally, we will present single-cell functional approaches to systematically examine the influence of the tumor microenvironment."

Oncology